Teachers Retirement System of The State of Kentucky Trims Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Teachers Retirement System of The State of Kentucky decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 4.9% during the fourth quarter, HoldingsChannel reports. The fund owned 15,598 shares of the biotechnology company’s stock after selling 810 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Repligen were worth $2,245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock valued at $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC grew its position in Repligen by 8.6% during the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after buying an additional 122,595 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after acquiring an additional 191,439 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after acquiring an additional 6,872 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Repligen by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after buying an additional 14,398 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 0.3 %

NASDAQ:RGEN opened at $144.75 on Friday. The firm has a market capitalization of $8.13 billion, a P/E ratio of -283.82, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average of $139.80 and a 200 day moving average of $145.79. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on RGEN. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $176.82.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.